

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/248665 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/713 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2022/064408

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:
27 May 2022 (27.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/194,395 28 May 2021 (28.05.2021) US
21183860.2 06 July 2021 (06.07.2021) EP

(71) Applicants: **NOVO NORDISK A/S** [DK/DK]; Novo Al-
lé, 2880 Bagsværd (DK). **DICERNA PHARMACEUTI-
CALS, INC.** [US/US]; 75 Hayden Avenue, Lexington,
02421 (US).

(72) Inventors: **DUDEK, Henryk**; Dicerna Pharmaceuticals,
Inc., 75 Hayden Avenue, Lexington, MA02421 (US). **HAN,
Wen**; Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue,
Lexington, MA02421 (US). **PURSELL, Natalie, Wayne**;
Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue, Lexing-
ton, MA02421 (US). **LAI, Chengjung**; Dicerna Pharma-
ceuticals, Inc., 75 Hayden Avenue, Lexington, MA02421
(US). **HAYNES, William, Geoffrey**; Novo Nordisk Ltd.,
Old Road Campus Roosevelt Drive, Oxford OX3 7FZ (GB).
DING, Zhihao; Beijing Novo Nordisk Pharmaceuticals Sci
& Tech Co. Ltd Building #2/#4, Bio-tech R&D Center,
No.20 Life Science Park Road, Beijing, Beijing 102206
(CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT
1 (MARC1) EXPRESSION

(57) Abstract: Oligonucleotides are provided herein that inhibit *MARC1* expression. Also provided are compositions including the
same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with *MARC1* expression.

WO 2022/248665 A1